2023
DOI: 10.1111/jdv.19063
|View full text |Cite
|
Sign up to set email alerts
|

Long‐term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two‐year results from a Phase III double‐blind, randomized controlled trial

Abstract: Background Secukinumab has previously demonstrated sustained efficacy and favourable safety for up to 52 weeks in paediatric patients (children and adolescents aged 6 to <18 years) with severe chronic plaque psoriasis (NCT02471144). Objective To investigate the long‐term (104 weeks) efficacy and safety of secukinumab. Methods After 52 weeks, patients continued to receive secukinumab low dose (LD [75/150 mg]) or high dose (HD [75/150/300 mg]). Patients on etanercept (0.8 mg/kg) until Week 52 entered follow‐up. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 26 publications
0
0
0
Order By: Relevance